In December 2023, Eli Lilly and Company, one of the major GLP-1 receptor agonist companies, announced the availability of Zepbound (tirzepatide) injection, a GLP-1 drug, in the U.S
That can look healthy but fail in real life if the user feels full after a few bites
The biggest concern is compounded Ozempic
To get started go ahead and review our affiliate marketing products and if you think you are ready to join the affiliate network sign up HERE
In the 64-week OASIS 4 trial (307 adults), mean weight loss was 13.6% under the treatment-policy analysis and 16.6% among participants who stayed on treatment, versus about 2% on placebo
Still, larger studies are needed to confirm the safety of L-carnitine during pregnancy